BCL2 and acute myeloid leukemia: ABCC1 (MRP1), an ATP-binding cassette transporter, mediates resistance to BCL2 inhibitors in AML by actively exporting BH3 mimetics such as venetoclax, AZD4320, and navitoclax, thereby reducing their intracellular concentrations and efficacy [96].